Weigel MT, Meinhold-Heerlein N, Bauerschlag DO, Schem C, Bauer M, Jonat W, Maass N, Mundhenke C (2009)
Publication Type: Journal article
Publication year: 2009
Book Volume: 273
Pages Range: 70-79
Journal Issue: 1
DOI: 10.1016/j.canlet.2008.07.040
Introduction: Imatinib mesylate is a tyrosine kinase receptor inhibitor targeted against PDGFR α and β, c-kit and bcr-abl. These receptors regulate cellular processes such as proliferation, differentiation, and survival. This study was performed to evaluate the effects of imatinib on breast cancer cell lines with respect to the activity of PDGFR β and Akt: a downstream modulator of cell growth and survival. Methods: Expression of imatinib targets was analyzed with reverse transciptase PCR and immunoblotting assays in the breast cell lines MDA MB 231, MCF 7, ZR 75-1, and T 47-D. Changes on receptor expression and phosphorylation status under imatinib were evaluated using drug concentrations of 2 to 10 μM. The anti-proliferative and pro-apoptotic effects of imatinib alone and in combination with vinorelbine were investigated with an MTT and TUNEL assay. Results: Imatinib inhibited growth and induced apoptosis of all cell lines examined. This effect was increased when combined with vinorelbine. A dose-dependent inhibitory effect on the phosphorylation of PDGFR β and Akt was detected. Conclusions: The growth inhibitory effect of imatinib on breast cell lines may be caused by inhibiting the activity of the tyrosine kinases PDGFR β and Akt. Imatinib is a promising novel drug for targeted therapy of breast cancer patients. © 2008 Elsevier Ireland Ltd. All rights reserved.
APA:
Weigel, M.T., Meinhold-Heerlein, N., Bauerschlag, D.O., Schem, C., Bauer, M., Jonat, W.,... Mundhenke, C. (2009). Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling. Cancer Letters, 273(1), 70-79. https://doi.org/10.1016/j.canlet.2008.07.040
MLA:
Weigel, Marion T., et al. "Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR β signalling." Cancer Letters 273.1 (2009): 70-79.
BibTeX: Download